Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 35K
2: EX-99.1 Miscellaneous Exhibit HTML 10K
7: R1 Document and Entity Information Document HTML 50K
9: XML IDEA XML File -- Filing Summary XML 12K
12: XML XBRL Instance -- bio-20240410_htm XML 18K
8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
4: EX-101.DEF XBRL Definitions -- bio-20240410_def XML 40K
5: EX-101.LAB XBRL Labels -- bio-20240410_lab XML 77K
6: EX-101.PRE XBRL Presentations -- bio-20240410_pre XML 41K
3: EX-101.SCH XBRL Schema -- bio-20240410 XSD 12K
10: JSON XBRL Instance as JSON Data -- MetaLinks 14± 21K
11: ZIP XBRL Zipped Folder -- 0000012208-24-000025-xbrl Zip 20K
(Address of principal executive offices, including zip code)
i(510)i724-7000
(Registrant’s telephone
number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iClass A Common Stock, Par Value $0.0001 per share
iBIO
iNew
York Stock Exchange
iClass B Common Stock, Par Value $0.0001 per share
iBIO.B
iNew
York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
i☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
April 10, 2024, Dr. Andrew Last, the Executive Vice President, Chief Operating Officer (and principal operating officer) of Bio-Rad Laboratories, Inc. (the “Company”), notified the Company that he intends to retire from his position by early September 2024.In order to ensure a smooth transition, Dr. Last will remain in his current position while the Company conducts a search for his successor.
A copy of the press release announcing the retirement of Dr. Last is furnished with this report as Exhibit
99.1.
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.